Cancer immunotherapy : immune suppression and tumor growth /
Saved in:
| Imprint: | Amsterdam ; Boston : Academic Press/Elsevier, c2007. |
|---|---|
| Description: | xiii, 409 p., [4] p. of plates : ill. (some col.) ; 27 cm. |
| Language: | English |
| Subject: | |
| Format: | Print Book |
| URL for this record: | http://pi.lib.uchicago.edu/1001/cat/bib/6822566 |
Table of Contents:
- Contributors
- Part I. Principles of Cancer Immunobiology
- 1. Introduction
- I. Overview
- II. Historical Background
- III. Looking Ahead: Marrying Chemotherapy and Immunotherapy
- IV. Parts of the Book
- References
- Further Reading
- 2. Cancer Immunoediting: From Immune Surveillance to Immune Escape
- I. Introduction
- II. Cancer Immune Surveillance
- III. Cancer Immunoediting
- IV. Concluding Remarks
- References
- 3. Immunosurveillance: Innate and Adaptive Antitumor Immunity
- I. Introduction
- II. Innate Antitumor Responses
- III. Innate Immune Cells
- IV. Adaptive Antitumor Responses
- V. The Interplay of Innate and Adaptive Antitumor Immunity
- VI. Conclusion
- References
- 4. Cytokine Regulation of Immune Tolerance to Tumors
- I. Introduction
- II. Cytokine Regulation of Immune Tolerance to Tumors
- III. Summary and Future Perspectives
- References
- 5. Immunological Sculpting: Natural Killer Cell Receptors and Ligands
- I. Introduction
- II. Activating Human NK Receptors
- III. Inhibitory NK Receptors
- IV. The Ly49 Receptor Family
- V. Immunotherapy Approaches
- VI. Conclusion
- References
- Further Reading
- 6. Immune Escape: Immunosuppressive Networks
- I. Introduction
- II. Imbalance Between Mature DCs and Immature DCs
- III. Imbalance Between Stimulatory and Inhibitory B7 Family Molecules
- IV. Imbalance Between Regulatory T Cells and Conventional T Cells
- V. Concluding Remarks
- References
- Part II. Cancer Therapeutics
- 7. Cytotoxic Chemotherapy in Clinical Treatment of Cancer
- I. Introduction
- II. DNA-Damaging Agents
- III. Antimetabolites
- IV. Antimitotics
- V. Chemotherapy Regimens
- References
- Useful Web Sites
- 8. Targeted Therapeutics in Cancer Treatment
- I. Introduction
- II. Cell Cycle
- III. The MAPK Family
- IV. Challenges in the Clinical Development of Signal Transduction Inhibitors
- References
- 9. Concepts in Pharmacology and Toxicology
- I. Introduction
- II. Concepts in Pharmacokinetics
- III. Concepts in Toxicology
- IV. Clinical Concerns for Pharmacology and Safety
- V. Conclusion
- References
- Further Reading
- 10. Cancer Immunotherapy: Challenges and Opportunities
- I. Introduction
- II. Prerequisites for Effective Cancer Immunotherapy: Identifying Tumor Antigens
- III. Adoptive ("Passive") Immunotherapy
- IV. Active-Specific Immunotherapy: Vaccines
- V. Cancer-Induced Immunosuppression Impinges on Immunotherapy
- VI. Cancer Immunotherapy in Mice Versus Humans
- VII. Immunotherapy and Cancer Stem Cells
- VIII. Autoimmunity Resulting from Cancer Immunotherapy
- IX. Conclusion and Future Considerations
- References
- 11. Cancer Vaccines
- I. Introduction
- II. Tumor Antigens
- III. Spontaneous Immunity to Cancer
- IV. Toleragenic Pressure on Immunity to Cancer
- V. Immune Responses to Conventional Vaccines
- VI. Cancer Vaccine Strategies
- VII. DNA Vaccines
- VIII. Challenges of Translation to the Clinic
- IX. Concluding Remarks
- References
- Further Reading
- Part III. Targets and Tactics to Improve Cancer Immunotherapy by Defeating Immune Suppression
- 12. Immunotherapy and Cancer Therapeutics: Why Partner?
- I. Introduction: Why Immunotherapy for Cancer?
- II. Immune Tolerance and Suppression: Multiple Layers of Negative Control
- III. T Cell Activation: A Rheostat for Tuning Immune Responses
- IV. Immune Modulation with Therapeutic Monoclonal Antibodies
- V. Therapeutics that Mitigate the Influence of CD4[superscript +]CD25[superscript +] Tregs
- VI. Endocrine and Biologically Targeted Therapy
- VII. Conclusion
- References
- 13. Immune Stimulatory Features of Classical Chemotherapy
- I. Introduction
- II. Tumor Cell Death
- III. Pathways to Immunogenicity
- IV. Chemotherapy and the Immune System
- V. A Practical Partnership: Chemotherapy and Immunotherapy
- VI. Effects of Chemotherapy on Human Antitumor Immunity and Chemoimmunotherapy Clinical Trials
- References
- 14. Dendritic Cells and Coregulatory Signals: Immune Checkpoint Blockade to Stimulate Immunotherapy
- I. Regulation of T Cell Responses to Antigen
- II. Regulatory T Cells
- III. Immune Checkpoints in the Tumor Microenvironment
- IV. Monoclonal Antibodies that Interfere with Coinhibitory Receptors on T Cells
- V. What Is the Most Effective Way to Use Checkpoint Inhibitors?
- References
- 15. Regulatory T Cells in Tumor Immunity: Role of Toll-Like Receptors
- I. Introduction
- II. Immune Cells in Immunosurveillance and Tumor Destruction
- III. TLRs and Their Signaling Pathways
- IV. TLRs in Innate Immunity, Inflammation, and Cancer Development
- V. Tumor-Infiltrating Immune Cells in the Tumor Microenvironment
- VI. Molecular Marker for CD4[superscript +] Tregs
- VII. Antigen Specificity of CD4[superscript +] Tregs
- VIII. Suppressive Mechanisms of Tregs
- IX. Functional Regulation of Tregs and Effector Cells by TLR Signaling
- X. Implications for Enhancing Antitumor Immunity
- XI. Conclusion
- References
- 16. Tumor-Associated Macrophages in Cancer Growth and Progression
- I. Introduction
- II. Macrophage Polarization
- III. Macrophage Recruitment at the Tumor Site
- IV. Tam Expression of Selected M2 Protumoral Functions
- V. Modulation of Adaptive Immunity by Tams
- VI. Targeting Tams
- VII. Concluding Remarks
- References
- 17. Tumor-Associated Myeloid-Derived Suppressor Cells
- I. Introduction
- II. Multiple Suppressive Mechanisms that Contribute to Immunosuppression in Individuals with Tumors
- III. MDSCs as a Key Cell Population that Mediates Tumor-Induced Immunosuppression
- IV. MDSCs' Use of Mechanisms to Mediate Effects on Multiple Target Cells
- V. MDSC Induction by Tumor-Derived Cytokines and Growth Factors
- VI. MDSC Linking of Inflammation and Tumor Progression
- VII. Agents Responsible for Reducing MDSC Levels
- VIII. Conclusions: Implications for Immunotherapy
- References
- Further Reading
- 18. Programmed Death Ligand-1 and Galectin-1: Pieces in the Puzzle of Tumor-Immune Escape
- I. Programmed Death Ligand 1 and Programmed Death 1 Interactions
- II. Galectin 1
- References
- Further Reading
- 19. Indoleamine 2,3-Dioxygenase in Immune Escape: Regulation and Therapeutic Inhibition
- I. Introduction
- II. IDO Function in T Cell Regulation
- III. Complex Control of IDO by Immune Regulatory Factors
- IV. Immune Tolerance Via IDO in Dendritic Cells
- V. IDO Dysregulation in Cancer Cells
- VI. IDO as a Target for Therapeutic Intervention
- VII. Discovery and Development of IDO Inhibitors
- VIII. Conclusion
- References
- Further Reading
- 20. Arginase, Nitric Oxide Synthase, and Novel Inhibitors of L-Arginine Metabolism in Immune Modulation
- I. Introduction
- II. NOS: Genes, Regulation, and Activity
- III. ARG: Genes, Regulation, and Activity
- IV. Immunoregulatory Activities of ARG and NOS
- V. Possible Physiological Role for L-ARG Metabolism in Immunity Control
- VI. NOS in Cancer
- VII. ARG in Cancer
- VIII. ARG and NOS Inhibitors: A Novel Class of Immune Adjuvants?
- IX. Conclusion and Perspectives
- References
- Further Reading
- Index
